OneSource Specialty Pharma Ltd
Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio
logical drug products in various injectable formats. It also offers end-to-end CDMO
services across all phases of pre-clinical
and clinical development and commercial
supply of biologics[1]
- Market Cap ₹ 18,034 Cr.
- Current Price ₹ 1,576
- High / Low ₹ 1,800 / 1,163
- Stock P/E
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE -11.8 %
- ROE -45.5 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
Cons
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -3.52%
- Company has a low return on equity of -47.7% over last 3 years.
- Debtor days have increased from 84.7 to 118 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Miscellaneous Industry: Miscellaneous
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| 21 | 132 | 39 | 172 | |
| 93 | 228 | 156 | 254 | |
| Operating Profit | -72 | -96 | -117 | -82 |
| OPM % | -337% | -72% | -303% | -48% |
| 1 | 4 | -525 | -143 | |
| Interest | 16 | 68 | 48 | 89 |
| Depreciation | 34 | 70 | 109 | 76 |
| Profit before tax | -121 | -230 | -799 | -390 |
| Tax % | 0% | 0% | 0% | 0% |
| -121 | -230 | -799 | -390 | |
| EPS in Rs | ||||
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 100% |
| TTM: | 344% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 58% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -48% |
| Last Year: | -45% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|
| Equity Capital | 2 | 4 | 4 | 4 | 4 |
| Reserves | 777 | 1,012 | 783 | 394 | 403 |
| 386 | 1,154 | 864 | 571 | 612 | |
| 98 | 275 | 363 | 457 | 264 | |
| Total Liabilities | 1,262 | 2,445 | 2,014 | 1,426 | 1,283 |
| 633 | 1,231 | 1,361 | 863 | 972 | |
| CWIP | 382 | 440 | 334 | 188 | 43 |
| Investments | 53 | 52 | 5 | 20 | 11 |
| 194 | 722 | 314 | 355 | 257 | |
| Total Assets | 1,262 | 2,445 | 2,014 | 1,426 | 1,283 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| -115 | -420 | -165 | -109 | |
| -210 | -685 | -66 | 506 | |
| 381 | 1,159 | 118 | -384 | |
| Net Cash Flow | 56 | 55 | -112 | 13 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| Debtor Days | 38 | 101 | 35 | 118 |
| Inventory Days | 87 | 1,720 | 2,354 | 665 |
| Days Payable | 758 | 408 | 1,606 | 419 |
| Cash Conversion Cycle | -633 | 1,414 | 784 | 363 |
| Working Capital Days | -1,116 | 251 | -1,939 | -255 |
| ROCE % | -10% | -12% | -12% |
Documents
Announcements
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
9h - Regulatory filing on mandatory and actual debt borrowing for FY, including shortfall details.
-
Announcement under Regulation 30 (LODR)-Change in Registered Office Address
9h - Company shifts registered office within Navi Mumbai city limits effective April 23, 2025.
-
Update On Scheme Of Arrangement
11 Apr - Submission of Audit Committee report on shareholder compensation.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
10 Apr - GMP certification granted by ANVISA for Unit 2 facility.
-
Announcement Under Regulation 30 SEBI(LODR) Regulations, 2015_Updates
9 Apr - OneSource receives Brazilian GMP approval for Unit 2.
Annual reports
No data available.
Concalls
-
Feb 2025Transcript PPT
Business Overview:[1]
OSSPL is a subsidiary of Strides Pharma
Ltd. The company is a Contract Development
and Manufacturing Organisation that caters
to several biopharma and biotech companies.
It covers the entire CDMO value chain, from clinical development to technology transfer
to commercial manufacture and regulatory assistance.